Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.46 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
| ▸ | KIF15 | Q9NS87 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584603 | 0.93 | MAP3K7 (0.46) | RAF1TLK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3582226 | 0.92 | PDPK1 (0.47) | RAF1TLK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3578300 | 0.92 | ALDH1A1 (0.45) | RAF1TLK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3584594 | 0.89 | PDPK1 (0.48) | RAF1TLK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3575699 | 0.84 | MAP3K7 (0.46) | RAF1TLK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3578296 | 0.84 | ALDH1A1 (0.46) | RAF1TLK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3581640 | 0.84 | RAF1 (0.42) | RAF1TLK2NTRK1JAK3GSK3B | |
| SCHEMBL4759187 | 0.83 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP3A4MAP3K7TAB1 | |
| SCHEMBL3581212 | 0.81 | NOX4 (0.46) | RAF1TLK2PDPK1GSK3B | |
| SCHEMBL3575692 | 0.81 | MAP3K7 (0.47) | RAF1TLK2ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010075197-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | RAF1 172/4885TLK2 304/4885ALDH1A1 2605/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | RAF1 69/4885TLK2 363/4885ALDH1A1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.